BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Le Page, Cécile ^a,b   Marineau, Alexandre ^a,b   Bonza, Patrick K ^a,b   Rahimi, Kurosh ^a   Cyr, Louis ^a,b   Labouba, Ingrid ^a,b   Madore, Jason ^a,b   Delvoye, Nathalie ^a,b   Mes Masson, Anne Marie ^a,b,c   Provencher, Diane M ^a,b   Cailhier, Jean François ^a,b,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Institut du Cancer de Montreal   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BTN3A2 ANTIBODY; CD20 ANTIBODY; CD206 ANTIBODY; CD3 ANTIBODY; CD4 ANTIBODY; CD68 ANTIBODY; CD8 ANTIBODY; PROTEIN BTN3A2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CD4+ T LYMPHOCYTE; CELL DENSITY; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; MACROPHAGE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PLASMID; PROGNOSIS; PROTEIN EXPRESSION; T LYMPHOCYTE; TISSUE MICROARRAY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BLOTTING, WESTERN; CELL LINE, TUMOR; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LECTINS, C-TYPE; LYMPHOCYTES, TUMOR-INFILTRATING; MANNOSE-BINDING LECTINS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN ISOFORMS; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES; TISSUE ARRAY ANALYSIS; TRANSFECTION;

EID: 84862023293     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038541     Document Type: Article

References (49)

1. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212 236.
2. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, (2007) Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 14: 195 208.
3. Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, et al (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 3621 3627.
4. Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, et al (2008) Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 26: 83 89.
5. Le Page C, Ouellet V, Quinn MC, Tonin PN, Provencher DM, (2008) BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 17: 913 920.
6. James LC, Keeble AH, Khan Z, Rhodes DA, Trowsdale J, (2007) Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc Natl Acad Sci U S A 104: 6200 6205.
7. Rhodes DA, Stammers M, Malcherek G, Beck S, Trowsdale J, (2001) The cluster of BTN genes in the extended major histocompatibility complex. Genomics 71: 351 362.
8. Tazi-Ahnini R, Henry J, Offer C, Bouissou-Bouchouata C, Mather IH, (1997) Cloning, localization, and structure of new members of the butyrophilin gene family in the juxta-telomeric region of the major histocompatibility complex. Immunogenetics 47: 55 63.
9. Linsley PS, Peach R, Gladstone P, Bajorath J, (1994) Extending the B7 (CD80) gene family. Protein Sci 3: 1341 1343.
10. Ogg SL, Weldon AK, Dobbie L, Smith AJ, Mather IH, (2004) Expression of butyrophilin (Btn1a1) in lactating mammary gland is essential for the regulated secretion of milk-lipid droplets. Proc Natl Acad Sci U S A 101: 10084 10089.
11. Banghart LR, Chamberlain CW, Velarde J, Korobko IV, Ogg SL, (1998) Butyrophilin is expressed in mammary epithelial cells from a single-sized messenger RNA as a type I membrane glycoprotein. J Biol Chem 273: 4171 4179.
12. Compte E, Pontarotti P, Collette Y, Lopez M, Olive D, (2004) Frontline: Characterization of BT3 molecules belonging to the B7 family expressed on immune cells. Eur J Immunol 34: 2089 2099.
13. Ling V, Wu PW, Spaulding V, Kieleczawa J, Luxenberg D, (2003) Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics 82: 365 377.
14. Sun X, Vale M, Leung E, Kanwar JR, Gupta R, (2003) Mouse B7-H3 induces antitumor immunity. Gene Ther 10: 1728 1734.
15. Loos M, Hedderich DM, Friess H, Kleeff J, (2010) B7-h3 and its role in antitumor immunity. Clin Dev Immunol 2010: 683875.
16. Steinberger P, Majdic O, Derdak SV, Pfistershammer K, Kirchberger S, (2004) Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol 172: 2352 2359.
17. Nguyen T, Liu XK, Zhang Y, Dong C, (2006) BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation. J Immunol 176: 7354 7360.
18. Arnett HA, Escobar SS, Gonzalez-Suarez E, Budelsky AL, Steffen LA, (2007) BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation. J Immunol 178: 1523 1533.
19. Smith IA, Knezevic BR, Ammann JU, Rhodes DA, Aw D, (2010) BTN1A1, the mammary gland butyrophilin, and BTN2A2 are both inhibitors of T cell activation. J Immunol 184: 3514 3525.
20. Yamazaki T, Goya I, Graf D, Craig S, Martin-Orozco N, (2010) A butyrophilin family member critically inhibits T cell activation. J Immunol 185: 5907 5914.
21. Bas A, Swamy M, Abeler-Dorner L, Williams G, Pang DJ, (2011) Butyrophilin-like 1 encodes an enterocyte protein that selectively regulates functional interactions with T lymphocytes. Proc Natl Acad Sci U S A 108: 4376 4381.
22. Yamashiro H, Yoshizaki S, Tadaki T, Egawa K, Seo N, (2010) Stimulation of human butyrophilin 3 molecules results in negative regulation of cellular immunity. J Leukoc Biol 88: 757 767.
23. Cubillos-Ruiz JR, Conejo-Garcia JR, (2010) It never rains but it pours: potential role of butyrophilins in inhibiting anti-tumor immune responses. Cell Cycle 10: 368 369.
24. Messal N, Mamessier E, Sylvain A, Celis-Gutierrez J, Thibult ML, (2011) Differential role for CD277 as a co-regulator of the immune signal in T and NK cells. Eur J Immunol 41: 3443 3454.
25. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, (2006) Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95: S161 192.
26. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, (2011) Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21: 419 423.
27. Le Page C, Puiffe ML, Meunier L, Zietarska M, de Ladurantaye M, (2009) BMP-2 signaling in ovarian cancer and its association with poor prognosis. J Ovarian Res 2: 4.
28. Zietarska M, Madore J, Diallo JS, Delvoye N, Saad F, (2010) A novel method of cell embedding for tissue microarrays. Histopathology 57: 323 329.
29. Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, (2009) A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One 4: e6529.
30. Barres V, Ouellet V, Lafontaine J, Tonin PN, Provencher DM, (2010) An essential role for Ran GTPase in epithelial ovarian cancer cell survival. Mol Cancer 9: 272.
31. Gavalas NG, Karadimou A, Dimopoulos MA, Bamias A, (2010) Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. Clin Dev Immunol 2010: 791603.
32. Mantovani A, Sica A, (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22: 231 237.
33. Torroella-Kouri M, Silvera R, Rodriguez D, Caso R, Shatry A, (2009) Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res 69: 4800 4809.
34. Wakabayashi MT, Lin PS, Hakim AA, (2008) The role of cytoreductive/debulking surgery in ovarian cancer. J Natl Compr Canc Netw 6: 803-810; quiz 811.
35. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203 213.
36. Al-Attar A, Shehata M, Durrant L, Moseley P, Deen S, (2010) T cell density and location can influence the prognosis of ovarian cancer. Pathol Oncol Res 16: 361 370.
37. Bosmuller H, Haitchi-Petnehazy S, Webersinke G, Marschon R, Roithmeier F, (2011) Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy. Virchows Arch 459: 183 191.
38. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, (2009) Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 4: e6412.
39. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102: 18538 18543.
40. Shah CA, Allison KH, Garcia RL, Gray HJ, Goff BA, (2008) Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. Gynecol Oncol 109: 215 219.
41. Stumpf M, Hasenburg A, Riener MO, Jutting U, Wang C, (2009) Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer 101: 1513 1521.
42. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, (2005) The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 11: 8326 8331.
43. Abeler-Dorner L, Swamy M, Williams G, Hayday AC, Bas A, (2012) Butyrophilins: an emerging family of immune regulators. Trends Immunol 33: 34 41.
44. Tetu B, Popa I, Bairati I, L'Esperance S, Bachvarova M, (2008) Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Mod Pathol 21: 1002 1010.
45. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677 686.
46. Mantovani A, Allavena P, Sica A, Balkwill F, (2008) Cancer-related inflammation. Nature 454: 436 444.
47. Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, (2006) Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 176: 5023 5032.
48. Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M, (2009) Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int 59: 300 305.
49. Allavena P, Germano G, Marchesi F, Mantovani A, (2010) Chemokines in cancer related inflammation. Exp Cell Res 317: 664 673.